ArticleRSC advances2021
MeFSAT: a curated natural product database specific to secondary metabolites of medicinal fungi.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Advances in the Isolation and Purification of Fungal Mycotoxins: From Classical Extraction to Precision Strategies.Molecules (Basel, Switzerland) · 2026Review
- Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer's disease: insights from experimental and computational approaches.Journal, genetic engineering & biotechnology · 2026Article
- Online sources of health-related traditional knowledge: content for a traditional medicine library.Bulletin of the World Health Organization · 2026Review
- CDK4/6 Inhibitors for Breast Cancer Therapy-A Review of Clinical Trials, Structural and Computational Approaches.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Identification of Novel Drug Molecules Against NS3-Like Helicase Enzyme of Alongshan Virus.Molecular biotechnology · 2025Article
- A Pilot Metabolomic Study for DiagnosingInternational journal of molecular sciences · 2025Article
- The GenusLife (Basel, Switzerland) · 2025Review
- Discovery of novel DdlA inhibitors in multidrug-resistant Pseudomonas aeruginosa using virtual screening, molecular docking, and dynamics simulations.Scientific reports · 2025Article
- Molluscicidal Screening ofJournal of fungi (Basel, Switzerland) · 2025Article
- Haplotype-Phased Chromosome-Level Genome Assembly ofJournal of fungi (Basel, Switzerland) · 2025Article
- Bioactive fungal metabolites as SIRT2 antagonists: A computational quest for cancer treatment.PloS one · 2025Article
- Discovering broad-spectrum inhibitors for SARS-CoV-2 variants: a cheminformatics and biophysical approach targeting the main protease.Frontiers in pharmacology · 2025Article
- Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer's disease therapy.PloS one · 2025Article
- Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches.Journal, genetic engineering & biotechnology · 2024Article
- Article
- Predicting fungal secondary metabolite activity from biosynthetic gene cluster data using machine learning.Microbiology spectrum · 2024Article
- Exploring the Role of Chemoinformatics in Accelerating Drug Discovery: A Computational Approach.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Cytotoxic Properties of Extreme Fungi's Bioactive Components-An Updated Metabolic and Omics Overview.Life (Basel, Switzerland) · 2023Review
- IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants.ACS omega · 2023Article
- Scaffold and Structural Diversity of the Secondary Metabolite Space of Medicinal Fungi.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungi are a rich source of secondary metabolites which constitutes a valuable and diverse chemical space of natural products. Medicinal fungi have been used in traditional medicine to treat human ailments for centuries. To date, there is no devoted resource on secondary metabolites and therapeutic uses of medicinal fungi. Such a dedicated resource compiling dispersed information on medicinal fungi across published literature will facilitate ongoing efforts towards natural product based drug discovery. Here, we present the first comprehensive manually curated database on Medicinal Fungi Secondary metabolites And Therapeutics (MeFSAT) that compiles information on 184 medicinal fungi, 1830 secondary metabolites and 149 therapeutics uses. Importantly, MeFSAT contains a non-redundant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.